Provided by Tiger Trade Technology Pte. Ltd.

Amylyx Pharmaceuticals

33.81
+0.06000.18%
Pre-market: 33.850.0400+0.12%06:54 EDT
Volume:1.82M
Turnover:61.22M
Market Cap:4.24B
PE:-23.63
High:34.21
Open:33.49
Low:32.99
Close:33.75
52wk High:41.14
52wk Low:9.15
Shares:125.46M
Float Shares:109.51M
Volume Ratio:0.82
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4309
EPS(LYR):-1.5305
ROE:-74.73%
ROA:-44.13%
PB:17.74
PE(LYR):-22.09

Loading ...

Amylyx Pharmaceuticals Inc - Cash Runway Expected to Fund Operations Into 2028

THOMSON REUTERS
·
May 07

Press Release: Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Dow Jones
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Amylyx management participates in Bank of America Health Care Conference fireside chat

Reuters
·
May 06

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults With Post-Bariatric Hypoglycemia

THOMSON REUTERS
·
May 05

Amylyx Pharmaceuticals Inc - Avexitide Phase 3 Lucidity Trial Topline Data Readout Anticipated in Q3 2026

THOMSON REUTERS
·
May 05

Amylyx Pharmaceuticals Inc - Commercial Launch of Avexitide Anticipated in 2027 IF Approved

THOMSON REUTERS
·
May 05

Amylyx Pharmaceuticals to report first-quarter financial results, host conference call

Reuters
·
Apr 30

Amylyx Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
Apr 23

Amylyx to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 08

A Look At Amylyx Pharmaceuticals (AMLX) Valuation As Avexitide Hits A Key Phase 3 LUCIDITY Milestone

Simply Wall St.
·
Apr 07

Amylyx Pharmaceuticals Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 25

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Economic Data Releases

MT Newswires Live
·
Mar 24

Amylyx completes enrollment in Phase 3 Lucidity trial of avexitide

TIPRANKS
·
Mar 24

Amylyx completes enrollment of 78 participants in Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia

Reuters
·
Mar 24

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Lucidity Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

THOMSON REUTERS
·
Mar 24

Amylyx Pharmaceuticals Inc - Topline Data Readout for Lucidity Trial Anticipated in Q3 2026

THOMSON REUTERS
·
Mar 24

Amylyx Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 19